Teva Pharmaceutical Industries (NYSE:TEVA) Given New $23.00 Price Target at Jefferies Financial Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target lifted by Jefferies Financial Group from $19.00 to $23.00 in a research note published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.

TEVA has been the subject of a number of other research reports. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an overweight rating in a report on Wednesday, June 5th. Piper Sandler reiterated an overweight rating and issued a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an underweight rating to a neutral rating and set a $14.00 price target for the company in a report on Friday, March 8th. StockNews.com cut shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating in a research report on Monday, May 20th. Finally, Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a buy rating in a research report on Thursday, May 30th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $17.00.

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of Teva Pharmaceutical Industries stock opened at $16.25 on Thursday. The company has a market cap of $18.41 billion, a P/E ratio of -39.63, a PEG ratio of 1.54 and a beta of 0.91. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a one year low of $7.42 and a one year high of $17.69. The firm has a fifty day moving average of $15.99 and a two-hundred day moving average of $13.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The firm had revenue of $3.82 billion for the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. On average, analysts forecast that Teva Pharmaceutical Industries will post 2.32 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at approximately $299,275.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. In the last three months, insiders sold 549,719 shares of company stock worth $9,353,736. Insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale grew its stake in shares of Teva Pharmaceutical Industries by 6.1% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 72,127 shares of the company’s stock valued at $1,036,000 after buying an additional 4,131 shares during the period. New Covenant Trust Company N.A. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $28,000. iA Global Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $1,436,000. California State Teachers Retirement System grew its stake in shares of Teva Pharmaceutical Industries by 13.9% during the 1st quarter. California State Teachers Retirement System now owns 1,374,231 shares of the company’s stock valued at $19,390,000 after buying an additional 167,786 shares during the period. Finally, Industrial Alliance Investment Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.